Novo Nordisk A/s

This study tested whether a new combination medicine called CagriSema can reduce kidney damage in people with chronic kidney disease, type 2 diabetes, and overweight or obesity. About 626 participants received either CagriSema, one of its two components alone, or a placebo for 35…

This study followed 336 adults with type 2 diabetes in the UK who were already prescribed Rybelsus (oral semaglutide). Researchers tracked changes in blood sugar levels and body weight over 8-10 months. The goal was to see how well the medication works in real-world settings, not…

This study tested a new medicine called Mim8 in 281 adults and teens with hemophilia A, including those whose bodies have developed inhibitors that block standard treatment. Mim8 is given as a weekly or monthly injection under the skin to help prevent bleeding episodes by replaci…

This study tested a new drug called NNC0487-0111, given as a shot under the skin, to see if it is safe and how it works in people who are overweight or obese. The trial involved 125 adults aged 18-55 with a BMI between 27 and 40. The main goal was to check for side effects and me…

This study tested a new weekly injection called CagriSema, which combines two medicines (semaglutide and cagrilintide), in over 2,700 adults with type 2 diabetes. The goal was to see if CagriSema lowers blood sugar and body weight better than either medicine alone or a placebo. P…

This study tested whether adding a new medicine (NNC0165-1875) to the existing weight-loss drug semaglutide helps people with obesity lose more weight. About 120 adults with a BMI between 30 and 45 took part. Participants received either the new medicine plus semaglutide or a pla…

This study tested a new once-weekly medicine called IcoSema (a mix of insulin and another drug) against daily insulin in 679 adults with type 2 diabetes whose blood sugar was not well controlled. Participants received either IcoSema weekly or daily insulin plus mealtime insulin f…

This study looked at whether using a smartphone app called 'Dose Check' together with the insulin Tresiba helps people with type 2 diabetes control their blood sugar. About 179 adults in Saudi Arabia took part for 6-7 months. The app helped them figure out the correct insulin dos…

This study tested a weekly injection of semaglutide (a weight-loss medicine) in 201 teenagers aged 12 to 17 with overweight or obesity. Over 15 months, participants received either the drug or a placebo, plus lifestyle advice. The main goal was to see how much their body mass ind…

This study tested whether a new way of making semaglutide works as well as the current version for controlling blood sugar. About 388 adults with type 2 diabetes received weekly injections for 28 weeks. The main goal was to see if the new version lowers blood sugar (HbA1c) just a…

This study tested a medicine called turoctocog alfa pegol (N8-GP) in 36 Chinese men with severe hemophilia A. The drug helps blood clot and was given as a shot into a vein to both treat and prevent bleeding episodes. Over about 7-8 months, researchers measured how many bleeds occ…

This early-stage study tested a new medicine, NNC0519-0130, in 161 people to see if it is safe and how it works in the body. The medicine aims to lower blood sugar and reduce appetite, which could help people with type 2 diabetes and overweight. Participants received either the m…

This study tested a new medicine (NNC0480-0389) combined with semaglutide, an existing diabetes drug, in 500 people with type 2 diabetes. The goal was to see how well different doses lower blood sugar and to pick the best doses for future studies. Participants took weekly injecti…

This study tested a new insulin called icodec that is injected just once a week, compared to a standard daily insulin (glargine), in 984 adults with type 2 diabetes who had never used insulin before. The main goal was to see if the weekly insulin controls blood sugar as well as t…

This study tested a weekly injection of semaglutide in 529 adults with obesity and a type of heart failure where the heart pumps normally but doesn't fill properly. The goal was to see if the drug improves heart failure symptoms, daily function, and body weight compared to a plac…

This study tested whether a combination of two medicines, cagrilintide and semaglutide (called CagriSema), can reduce how much people with overweight or obesity eat and how hungry they feel. 62 participants were randomly assigned to receive either CagriSema or a placebo for about…

This early-stage study tested a new medicine called NNC0487-0111 in 36 Chinese adults who were overweight or obese. The main goal was to check if the drug is safe and how the body processes it. Participants received either the medicine or a placebo, and the study lasted up to 53 …

This study looked at whether two weight-loss medications, cagrilintide and semaglutide, can be given together in one injection instead of two separate shots. Forty adults with overweight or obesity took part. The main goal was to measure how much of each drug gets into the blood …

This study looked at how the kidneys affect a new medicine called NNC0519-0130 for type 2 diabetes. 36 adults with different levels of kidney function (from normal to severely reduced) received one dose of the drug. Researchers measured the drug levels in their blood to see if ki…

This study tested a new tablet form of semaglutide (a diabetes drug) in 121 healthy men. Researchers wanted to see how different amounts of water (50 or 120 mL) and delays before breakfast (30, 60, or 120 minutes) affect drug levels in the blood. Participants took one tablet dail…

This study looked at whether a new medicine for type 2 diabetes, NNC0519-0130, changes how the body processes a common birth control pill. It also checked if the drug affects how fast the stomach empties. The study involved 47 healthy postmenopausal women and lasted about 35 week…

This early-stage study tested a new medicine called NNC0581-0001 in 48 adults to see if it is safe and how the body handles it. Some participants were healthy, and others had fatty liver (hepatic steatosis). Each person received either the drug or a placebo as a single injection …

This early-stage study tested a new experimental drug, NNC0113-6856, in 70 healthy men to see if it is safe and how it moves through the body. Participants received either a single oral dose or an injection into a vein. The goal was to gather initial safety data and measure drug …